MGC Pharmaceuticals Limited (MXC.AX)
| Previous close | 0.6950 |
| Open | 0.6950 |
| Bid | 0.6750 x 125665700 |
| Ask | 0.6950 x 8008500 |
| Day's range | 0.6750 - 0.6950 |
| 52-week range | 0.0010 - 2.0000 |
| Volume | |
| Avg. volume | 2,389,498 |
| Market cap | 23.916M |
| Beta (5Y monthly) | 1.34 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -7.1000 |
| Earnings date | 26 Feb 2024 - 01 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 0.04 |
PR NewswireHistoric Milestone: UK Patients Receive First CannEpil® Delivery through 'I AM Billy Foundation' and GMC Specialist Register
MGC Pharmaceuticals Ltd. (LSE: MXC), (ASX: MXC), (OTC: MGCLF), a leading European pharmaceutical firm specializing in plant-derived medications, announced today that its ground-breaking Investigational Medicinal Product (IMP), CannEpil®, has been successfully imported and received by its first patients in the United Kingdom.
- PR Newswire
MGC Pharma's CannEpil® Now Accessible to UK Patients on Named Patient Request Basis
MGC Pharmaceuticals Ltd. (LSE: MXC), (ASX: MXC), (OTC: MGCLF), a European based pharmaceutical company specializing in the development and supply of affordable, ethically produced plant-inspired medicines, announces that its proprietary product CannEpil® is now available to patients in the UK by Named Patient Request.
- PR Newswire
ArtemiC TM Listed as an OTC Drug in the USA; AMC Places US$2m Order
MGC Pharmaceuticals Ltd. (LSE: MXC), (ASX: MXC), (OTC: MGCLF), a European based bio-pharma company specializing in the development and supply of affordable, ethically produced plant-inspired medicines, announces that its innovative product ArtemiC™ has recently been listed as an over-the-counter (OTC) drug in the USA on the FDA National Drug Code (NDC) Database under the code 83278. Facilitated by the company's US-based supply and distribution partner, AMCPharma USA, LLC. (AMC), ArtemiC™ will be
